You are here: Industry Insights > Diabetes

News List

EastGate Biotech Signs Strategic Alliance Agreement with MJ Biopharm for Insulin API Supply pharmpacpeutical-technology
March 20, 2019
EastGate Biotech Corp., a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, entered into a long term strategic alliance with MJ Biopharm (www.mjgroup.c
FDA Warns Homeopathic Company About Illegal Product Claims drugs
March 20, 2019
Nutra Pharma Corp. has been warned about illegal marketing of unapproved homeopathic products with claims that they can treat addiction and chronic pain from serious conditions such as cancer, diabetes, shingles, and fibromyalgia, the U.S. Food and Drug A
Diabetes drug effective against heart failure in wide spectrum of patients worldpharmanews
March 19, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are especially pronounced in those with reduced ejection fraction...
AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes pharmafocusasia
March 07, 2019
AnTolRx, Inc., a private biotechnology company and a leader in immune tolerance, today announced that Pfizer Inc has exercised the option granted under a June 2016 agreement to license an immune...
Statins might be linked to increased risk of diabetes europeanpharmaceuticalreview
March 07, 2019
Researchers have identified a possible association between use of statins and developing type 2 diabetes after following patients for 15 years…
Sanofi, boosted by partnerships, lays out connected tech ambitions in diabetes fiercepharma
March 07, 2019
Technology solutions are key to the future of diabetes—especially personalized, "smart" connected tech.
Diabetes coverage is improving, but could a shake-up be on the way with Novo’s oral semaglutide? fiercepharma
March 06, 2019
Payer pressure has been squeezing diabetes drugs, leading to some major sales difficulties and layoff rounds. As Bernstein analyst Wimal Kapadia observes, things are on the mend in terms of 2019 formulary coverage, but one drug could “disrupt them all.”
Lilly to Introduce Lower-Priced Insulin americanpharmaceuticalreview
March 06, 2019
Eli Lilly and Company announced the company will introduce a lower-priced version of Humalog® (insulin lispro injection 100 units/mL) in the United States, providing people with diabetes an insulin option that will have a list price 50 percent lower than
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors worldpharmanews
March 06, 2019
Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology.
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors worldpharmanews
March 06, 2019
Novo Nordisk announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 38 39 Next page